FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2811301013> ?p ?o ?g. }

• W2811301013 endingPage "440" @default.
• W2811301013 startingPage "429" @default.
• W2811301013 abstract "Arginine depletion interferes with pyrimidine metabolism as well as DNA damage repair pathways. Preclinical data indicates that pairing pegylated arginine deiminase (ADI-PEG 20) with fluoropyrimidines or platinum enhances cytotoxicity in vitro and in vivo in arginine auxotrophs. This is a single-center, open-label, phase 1 trial of ADI-PEG 20 and modified FOLFOX6 (mFOLFOX6) in treatment-refractory hepatocellular carcinoma (HCC) and other advanced gastrointestinal tumors. A 3 + 3 dose escalation design was employed to assess safety, tolerability, and determine the recommended phase 2 dose (RP2D) of ADI-PEG 20. A RP2D expansion cohort for patients with HCC was employed to define the objective response rate (ORR). Secondary objectives were to estimate progression-free survival (PFS), overall survival (OS), and to explore pharmacodynamics and immunogenicity. Eligible patients were treated with mFOLFOX6 intravenously biweekly at standard doses and ADI-PEG-20 intramuscularly weekly at 18 (Cohort 1) or 36 mg/m2 (Cohort 2 and RP2D expansion). Twenty-seven patients enrolled—23 with advanced HCC and 4 with other gastrointestinal tumors. No dose-limiting toxicities were observed in cohort 1 or 2. The RP2D for ADI-PEG 20 was 36 mg/m2 weekly with mFOLFOX6. The most common any grade adverse events (AEs) were thrombocytopenia, neutropenia, leukopenia, anemia, and fatigue. Among the 23 HCC patients, the most frequent treatment-related Grade ≥ 3 AEs were neutropenia (47.8%), thrombocytopenia (34.7%), leukopenia (21.7%), anemia (21.7%), and lymphopenia (17.4%). The ORR for this group was 21% (95% CI 7.5–43.7). Median PFS and OS were 7.3 and 14.5 months, respectively. Arginine levels were depleted with therapy despite the emergence of low levels of anti-ADI-PEG 20 antibodies. Arginine depletion at 4 and 8 weeks and archival tumoral argininosuccinate synthetase-1 levels did not correlate with response. Concurrent mFOLFOX6 plus ADI-PEG-20 intramuscularly at 36 mg/m2 weekly shows an acceptable safety profile and favorable efficacy compared to historic controls. Further evaluation of this combination is warranted in advanced HCC patients." @default.
• W2811301013 created "2018-07-10" @default.
• W2811301013 creator A5007808102 @default.
• W2811301013 creator A5008766773 @default.
• W2811301013 creator A5016800598 @default.
• W2811301013 creator A5028665323 @default.
• W2811301013 creator A5039386405 @default.
• W2811301013 creator A5046852633 @default.
• W2811301013 creator A5051220325 @default.
• W2811301013 creator A5058782121 @default.
• W2811301013 creator A5062412110 @default.
• W2811301013 creator A5065435809 @default.
• W2811301013 creator A5070326975 @default.
• W2811301013 creator A5081273660 @default.
• W2811301013 creator A5084948691 @default.
• W2811301013 creator A5090149957 @default.
• W2811301013 date "2018-07-03" @default.
• W2811301013 modified "2023-10-16" @default.
• W2811301013 title "A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies" @default.
• W2811301013 cites W1594929170 @default.
• W2811301013 cites W1843927557 @default.
• W2811301013 cites W1966242225 @default.
• W2811301013 cites W1968261414 @default.
• W2811301013 cites W1971837077 @default.
• W2811301013 cites W1987246871 @default.
• W2811301013 cites W2019607817 @default.
• W2811301013 cites W2027169351 @default.
• W2811301013 cites W2041076445 @default.
• W2811301013 cites W2101459399 @default.
• W2811301013 cites W2110195508 @default.
• W2811301013 cites W2129920232 @default.
• W2811301013 cites W2161332892 @default.
• W2811301013 cites W2166112130 @default.
• W2811301013 cites W2168974457 @default.
• W2811301013 cites W2342912708 @default.
• W2811301013 cites W2345381093 @default.
• W2811301013 cites W2472071085 @default.
• W2811301013 cites W2512678052 @default.
• W2811301013 cites W2560499218 @default.
• W2811301013 cites W2580528384 @default.
• W2811301013 cites W2604413507 @default.
• W2811301013 cites W2606367731 @default.
• W2811301013 cites W2620917021 @default.
• W2811301013 cites W2736924762 @default.
• W2811301013 cites W2749938176 @default.
• W2811301013 cites W2792999042 @default.
• W2811301013 cites W2808082897 @default.
• W2811301013 cites W2889699338 @default.
• W2811301013 doi "https://doi.org/10.1007/s00280-018-3635-3" @default.
• W2811301013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6850802" @default.
• W2811301013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29971467" @default.
• W2811301013 hasPublicationYear "2018" @default.
• W2811301013 type Work @default.
• W2811301013 sameAs 2811301013 @default.
• W2811301013 citedByCount "33" @default.
• W2811301013 countsByYear W28113010132018 @default.
• W2811301013 countsByYear W28113010132019 @default.
• W2811301013 countsByYear W28113010132020 @default.
• W2811301013 countsByYear W28113010132021 @default.
• W2811301013 countsByYear W28113010132022 @default.
• W2811301013 countsByYear W28113010132023 @default.
• W2811301013 crossrefType "journal-article" @default.
• W2811301013 hasAuthorship W2811301013A5007808102 @default.
• W2811301013 hasAuthorship W2811301013A5008766773 @default.
• W2811301013 hasAuthorship W2811301013A5016800598 @default.
• W2811301013 hasAuthorship W2811301013A5028665323 @default.
• W2811301013 hasAuthorship W2811301013A5039386405 @default.
• W2811301013 hasAuthorship W2811301013A5046852633 @default.
• W2811301013 hasAuthorship W2811301013A5051220325 @default.
• W2811301013 hasAuthorship W2811301013A5058782121 @default.
• W2811301013 hasAuthorship W2811301013A5062412110 @default.
• W2811301013 hasAuthorship W2811301013A5065435809 @default.
• W2811301013 hasAuthorship W2811301013A5070326975 @default.
• W2811301013 hasAuthorship W2811301013A5081273660 @default.
• W2811301013 hasAuthorship W2811301013A5084948691 @default.
• W2811301013 hasAuthorship W2811301013A5090149957 @default.
• W2811301013 hasBestOaLocation W28113010132 @default.
• W2811301013 hasConcept C126322002 @default.
• W2811301013 hasConcept C143998085 @default.
• W2811301013 hasConcept C197934379 @default.
• W2811301013 hasConcept C2776694085 @default.
• W2811301013 hasConcept C2777063308 @default.
• W2811301013 hasConcept C2778019345 @default.
• W2811301013 hasConcept C2778248108 @default.
• W2811301013 hasConcept C2778375690 @default.
• W2811301013 hasConcept C2778850193 @default.
• W2811301013 hasConcept C2780873365 @default.
• W2811301013 hasConcept C71924100 @default.
• W2811301013 hasConcept C72563966 @default.
• W2811301013 hasConcept C90924648 @default.
• W2811301013 hasConceptScore W2811301013C126322002 @default.
• W2811301013 hasConceptScore W2811301013C143998085 @default.
• W2811301013 hasConceptScore W2811301013C197934379 @default.
• W2811301013 hasConceptScore W2811301013C2776694085 @default.
• W2811301013 hasConceptScore W2811301013C2777063308 @default.
• W2811301013 hasConceptScore W2811301013C2778019345 @default.
• W2811301013 hasConceptScore W2811301013C2778248108 @default.
• W2811301013 hasConceptScore W2811301013C2778375690 @default.

• next